Sai Yendamuri, M.D., a thoracic surgeon at Roswell Park Comprehensive Cancer Center in Buffalo, New York, speaks to Fox News Digital about whether weight-loss drugs could reduce cancer risk.

GLP-1 medications may provide health benefits that extend beyond weight loss, according to a growing body of research.

From reducing cardiovascular risks to potentially easing joint pain and inflammation, studies suggest these drugs may affect multiple systems throughout the body.

Here are seven potential benefits beyond shedding pounds.

POPULAR WEIGHT-LOSS STRATEGY SHOWS SURPRISING POTENTIAL FOR CHRONIC PAIN RELIEF

Research suggests semaglutide — the active ingredient in Ozempic and Wegovy — may provide cardiovascular benefits beyond those associated with weight loss.

A major study published in The Lancet found that semaglutide reduced the risk of heart attacks, strokes and cardiovascular death among people with existing cardiovascular disease and overweight or obesity. The benefits were observed across different body weights and were not fully explained by weight loss.

Semaglutide has been shown to reduce cardiovascular risks, with benefits that appear to extend beyond weight loss. (iStock)

GLP-1 medications have been linked to reduced joint pain, although researchers are still investigating how much of the benefit comes from weight loss versus other effects.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

The STEP 9 clinical trial, published in the New England Journal of Medicine, found that semaglutide significantly reduced knee osteoarthritis pain and improved physical function among adults with obesity.

Research suggests GLP-1 medications may help reduce knee osteoarthritis pain, although their ability to repair damaged cartilage has not been established. (iStock)

GLP-1 medications may help protect kidney function through several mechanisms, including improvements in blood sugar, blood pressure and inflammation.

GLP-1 BOOM COULD RESHAPE RESTAURANT BARS AS DINERS CUT BACK ON ALCOHOL

In the landmark FLOW trial, published in the New England Journal of Medicine, semaglutide reduced the risk of major kidney-related complications and cardiovascular death by 24% among patients with type 2 diabetes and chronic kidney disease.

MASH, or metabolic dysfunction-associated steatohepatitis, is a more severe form of fatty liver disease involving inflammation and liver cell damage.

Research suggests GLP-1 medications may help improve liver health, although the extent to which these benefits occur independently of weight loss remains under investigation.

Clinical trials have found that semaglutide can slow the progression of kidney disease in certain patients. (iStock)

A clinical trial published in the New England Journal of Medicine found that semaglutide improved liver tissue findings among patients with MASH, including reductions in inflammation and liver scarring.

Researchers found that 62.9% of semaglutide recipients experienced resolution of MASH without worsening liver fibrosis, compared with 34.3% receiving placebo.

Real-world research presented at the European Respiratory Society Congress has linked GLP-1 medications to fewer asthma attacks and COPD flare-ups.

Researchers believe the drugs' potential anti-inflammatory effects may play a role, although additional studies are needed to determine whether the medications directly improve respiratory health.

CLICK HERE FOR MORE HEALTH STORIES

The brain contains GLP-1 receptors in regions involved in regulating appetite, emotions, motivation and responses to rewards.

Emerging research suggests semaglutide may have potential benefits for mental health and addiction.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

An observational study published on the preprint server medRxiv linked semaglutide use to lower rates of substance-related and mood disorders. However, the findings have not been peer-reviewed and do not establish that the medication caused the reductions.

Preliminary research has linked semaglutide use to lower rates of certain substance-related and mood disorders, although further studies are needed. (iStock)

GLP-1-based medications are also being investigated for their potential benefits in inflammatory skin conditions, including psoriasis.

A clinical trial published in JAMA Dermatology found that adding tirzepatide to an existing psoriasis treatment improved skin clearance among adults with moderate to severe psoriasis and overweight or obesity.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Researchers are continuing to investigate whether these benefits result from weight loss, reduced inflammation or a combination of factors.

The effects of GLP-1 medications can vary by drug and individual, and patients should consult a healthcare provider about potential risks and benefits.

Khloe Quill is a lifestyle writer with Fox News Digital. She and the lifestyle team cover a range of story topics including food and drink, travel, and health. 

Stay up-to-date on the biggest health and wellness news with our weekly recap.

By entering your email and clicking the Subscribe button, you agree to the Fox News 
        Privacy Policy
       and 
        Terms of Use
      , and
      agree to receive content and promotional communications from Fox News. You understand that you can
      opt-out at any time.

Subscribed

You've successfully subscribed to this newsletter!